NeurAxon Raises $8.75M in Debt Financing

Private Equity Hub -- NeurAxon Inc., a drug company focused on pain management, has raised $8.75 million of unsecured subordinated 2.0% convertible debentures. CTI Life Sciences Fund led the deal, and was joined by existing NeurAxon investors Delphi Ventures, OrbiMed Advisors, Ventures West Capital, H.I.G. Ventures, BDC Venture Capital, NeuroVentures Fund and Lawrence Bloch. The company previously raised over $32 million in VC funding, and has offices in both Waltham, Mass. and Toronto.